Under terms of the deal, Stoke will spearhead global development of zorevunersen, while Biogen will receive exclusive rights ...
Biogen and Stoke Therapeutics have announced a partnership aimed at advancing a disease-modifying treatment for Dravet ...
Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...
The company now has rights to the potential first-in-class drug – called zorevunersen – outside the US, Canada, and Mexico, where Bedford, Massachusetts-based Stoke has retained exclusive ...
Under the terms of the deal, Bedford, Mass.-based Stoke STOK will retain exclusive rights for the treatment called zorevunersen in the U.S., Canada and Mexico, while Cambridge, Mass.-based Biogen ...
Barchart on MSN2d
2 ‘Strong Buy’ Stocks Under $10 Set to Surge as Much as 331%Generally, a “Strong Buy” rating on Wall Street indicates that analysts believe the stock will appreciate and outperform the ...
Learn more about whether Biogen Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor grades, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback